Our Science
Our Story
News
Connect
Globe Newswire
August 1, 2024
Featured article
Read More
Public Relations
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
READ MORE
DOWNLOAD
PR
April 7, 2024
Publications
American Association for Cancer Research (AACR)
In vitro modeling of antigen-driven exhaustion in human CAR T cells
"Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity"
OPB-101: An optimized mesothelin-specific CAR T cell product expressing CD8-targeted IL-2/15 and engineered to resist T cell exhaustion
April 4, 2024
Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting
November 3, 2023
Society for Immunotherapy of Cancer (SITC)
Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies
October 31, 2023
Outpace Bio to present new data on tumor-restricted IL-12 designed leveraging OutSmart technology to enhance solid tumor T cell therapies at SITC 2023
October 9, 2023
Cancer Cell
Building smart CAR T cell therapies: The path to overcome current challenges
1
All
August 2, 2023
In The News
GeekWire
Seattle startups move into growing science cluster in South Lake Union
July 10, 2023
How AI is changing the way scientists engineer drugs, biosensors, enzymes and more
May 26, 2023
Endpoints News
Outpace Bio expands cell therapy R&D, nets research collaborations in Seattle
May 11, 2023
BioCentury
Keeping up with the protein designers
June 28, 2022
Biotech startups join AWS and other partners in open-source project to help design new proteins
February 21, 2022
Fred Hutch Cancer Center
Red Light, Green Light: Precise cell targeting with Co-LOCKR
May 22, 2023
Outpace Bio expands Seattle presence with cell therapy research hub & collaborations with leading experts in protein design & cancer immunotherapy
May 18, 2023
Outpace Bio to present new data on OutSmart™ IL-2/15, a CAR T cell-produced designed cytokine with tumor-localized immune cell activity, at the 2023 annual meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 9, 2023
Outpace Bio, a leader in protein design for cell therapy, announces presentation at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
August 1, 2023
American Society for Gene & Cell Therapy (ASGCT)
OutSmart™ IL-2/15 Safely Stimulates CAR T Proliferation and Persistence in the Tumor while Limiting Regulatory T Cell Activation
The Outpace Press Kit is designed to help journalists research Outpace. Please contact our communications team if you need more information or to schedule an interview.